Calcium and Phosphate Regulation

Calcium in the body exists in three pools with very different sizes and turnover rates. Roughly 99% of total body calcium — about 1 kg in an adult — is locked in bone as hydroxyapatite crystal, a stable structural and mineral reserve. The remaining ~1% circulates in plasma and soft tissue, and it is this small, dynamic pool whose concentration is regulated so precisely. Plasma calcium itself is split three ways: about 50% free (ionized) calcium, the biologically active form; about 40% bound to plasma proteins (mainly albumin); and about 10% complexed with anions like citrate and phosphate. Only the ionized fraction is sensed and regulated — a clinical detail that matters because a low-albumin patient can have a low total calcium but a normal ionized calcium. Phosphate regulation is coupled to calcium regulation but moves in the opposite direction under PTH control, because calcium and phosphate together form calcium phosphate salts, and because the same organs (bone, kidney, gut) handle both ions. The key regulatory principle is that calcium homeostasis is prioritized over phosphate homeostasis: the body will sacrifice phosphate balance, and even bone mineral itself, to defend plasma ionized calcium, because acute hypocalcemia is far more immediately dangerous (cardiac and neuromuscular) than hypophosphatemia. Three hormones execute this defense. Parathyroid hormone (PTH), an 84-amino-acid peptide from the four parathyroid glands, is the primary and fastest-acting defender against hypocalcemia. Calcitriol (1,25-dihydroxyvitamin D₃), a steroid hormone derived from cholesterol-related precursors and activated through skin, liver, and kidney, works on a slower timescale to boost intestinal absorption of both calcium and phosphate. Calcitonin, from thyroid parafollicular (C) cells, is a peptide hormone that opposes PTH's bone-resorbing action, though its physiological importance in adult humans is modest compared to the other two.

Step 1 — Sensing. Parathyroid chief cells express a calcium-sensing receptor (CaSR), a class C G-protein-coupled receptor, on their plasma membrane. Extracellular ionized calcium is the ligand. When plasma calcium falls, fewer CaSR molecules are occupied; this reduces Gq-PLC signaling and intracellular calcium/IP₃ inside the parathyroid cell, which — counterintuitively, since it is an inhibitory pathway — removes the brake on PTH secretion, so PTH release rises. Conversely, high plasma calcium strongly activates CaSR and PLC-mediated signaling, which suppresses PTH exocytosis. This is a direct, receptor-level, sub-minute feedback loop — no hypothalamus or pituitary intermediary is required.

Step 2 — PTH acts on bone. PTH receptors (PTH1R, a Gs-coupled GPCR working through cAMP/PKA) are on osteoblasts, not osteoclasts, which have no PTH receptors themselves. Osteoblasts respond to PTH by increasing expression of RANKL (receptor activator of NF-κB ligand) on their surface and decreasing osteoprotegerin (OPG), a decoy receptor that normally blocks RANKL. RANKL binds RANK on osteoclast precursors, driving their differentiation, fusion, and activation into mature bone-resorbing osteoclasts. Activated osteoclasts secrete acid (via H⁺-ATPase) and proteases (cathepsin K) that dissolve hydroxyapatite and degrade collagen matrix, releasing both calcium and phosphate into plasma. Sustained high PTH thus increases both ions from bone — but PTH's renal actions then selectively dump the phosphate (see Step 3), so the net effect is a calcium rise with phosphate held low or normal.

Step 3 — PTH acts on kidney. In the distal convoluted tubule, PTH increases the number and activity of apical TRPV5 calcium channels and basolateral Ca²⁺-ATPase/Na⁺-Ca²⁺ exchangers, increasing calcium reabsorption — directly conserving filtered calcium that would otherwise be lost in urine. Simultaneously, in the proximal tubule, PTH inhibits the sodium-phosphate cotransporter NaPi-IIa, causing phosphaturia (increased phosphate excretion). This dual action is elegant: it raises calcium while lowering phosphate, preventing the two ions from simply recombining and precipitating as calcium phosphate in soft tissue — a genuine physiological safeguard against ectopic calcification.

Step 4 — PTH activates vitamin D. In the proximal tubule, PTH stimulates the enzyme 1α-hydroxylase (CYP27B1), which converts 25-hydroxyvitamin D₃ (the major circulating storage form, made in the liver) into 1,25-dihydroxyvitamin D₃ — calcitriol, the active hormone. This is the rate-limiting, hormonally controlled step of the entire vitamin D activation pathway.

Step 5 — Calcitriol acts on gut, bone, and kidney. Calcitriol is lipophilic and binds an intracellular vitamin D receptor (VDR), a nuclear receptor that heterodimerizes with retinoid X receptor (RXR) and binds vitamin D response elements in DNA, altering gene transcription — a genomic mechanism, slower (hours) than PTH's largely cAMP-driven actions (minutes). In intestinal enterocytes, calcitriol upregulates calbindin (a calcium-binding transport protein), TRPV6 apical calcium channels, and basolateral calcium pumps, increasing active transcellular calcium absorption; it also increases intestinal phosphate absorption via NaPi-IIb transporters. In bone, calcitriol works with PTH to promote osteoclast differentiation (also via RANKL) — but the physiological priority of calcitriol is to supply calcium via the gut, reducing the need for bone resorption in the well-fed state. In the kidney, calcitriol modestly enhances calcium reabsorption alongside PTH.

Step 6 — Calcitonin opposes bone resorption. When plasma calcium rises (e.g., after a calcium-rich meal), thyroid C cells detect this (also via CaSR-related mechanisms) and secrete calcitonin. Calcitonin receptors on osteoclasts (a Gs-coupled GPCR) directly inhibit osteoclast motility and resorptive activity, retracting the ruffled border and reducing bone breakdown, thereby lowering plasma calcium. In humans, however, total thyroidectomy (removing calcitonin's source) or total parathyroidectomy plus calcitonin-secreting tumors do not produce dramatic derangements of plasma calcium — indicating calcitonin is a fine-tuning, largely dispensable player in adult mineral homeostasis, more important perhaps during growth or high calcium turnover states like pregnancy.

Integration — the overall loop. A fall in plasma ionized calcium is detected within minutes by parathyroid CaSR, triggering PTH release. PTH acts fast on kidney (renal calcium reabsorption up, phosphate excretion up) and within hours on bone (resorption up via RANKL/OPG) while also stimulating calcitriol synthesis over a slower timescale (many hours to days), which then boosts intestinal calcium absorption as a longer-term, dietary-dependent compensation. As plasma calcium normalizes, CaSR occupancy rises, PTH secretion is suppressed, and the system returns to its set point — a textbook negative feedback loop, but distinguished from a simple thermostat by its use of three organs and three time-constants working in series and parallel.

Parathyroidectomy and tetany (late 19th century, refined early 20th century). Surgeons removing the thyroid gland occasionally noted that patients developed fatal tetanic convulsions — violent, sustained muscle spasms — a mystery until it was recognized that small parathyroid glands, easily mistaken for thyroid tissue or lymph nodes, were being inadvertently removed along with the thyroid. Eugene Gley and others in the 1890s showed experimentally in animals that surgical removal of the parathyroid glands specifically (sparing the thyroid) reliably produced tetany and death, while removal of thyroid alone (sparing parathyroids) did not. This established that the parathyroid glands, not the thyroid, were essential for preventing hypocalcemic tetany — the first solid evidence that a distinct hormone from these glands controlled calcium. Later work (Collip, 1925) isolated a parathyroid extract that, when injected into parathyroidectomized or normal animals, rapidly raised plasma calcium, directly demonstrating the extract contained a calcium-raising hormone (PTH) and that its effect was dose-dependent and reversible.

Albright's studies and the discovery of PTH's renal phosphate action (1930s–40s). Fuller Albright and colleagues studied patients with hyperparathyroidism and found not only elevated plasma calcium but consistently low plasma phosphate and high urinary phosphate excretion. By correlating gland pathology (parathyroid adenomas found at surgery) with these biochemical patterns, and by observing that surgical removal of the adenoma normalized both calcium and phosphate, Albright's clinical-pathological correlations were central evidence that PTH's actions were not confined to bone but included a specific renal phosphaturic effect — a finding later confirmed directly using isolated perfused kidney and micropuncture techniques that measured tubular fluid phosphate concentration before and after PTH infusion, showing reduced proximal tubular phosphate reabsorption.

Discovery of the calcium-sensing receptor (Brown et al., 1993). For decades it was known parathyroid cells responded directly to extracellular calcium, but the sensing molecule was unidentified. Edward Brown and colleagues at Harvard cloned a novel G-protein-coupled receptor from bovine parathyroid tissue, expressed it in Xenopus oocytes and human embryonic kidney cells, and showed that raising extracellular calcium concentration in the bath activated intracellular calcium signaling (via IP₃-mediated calcium release) specifically in cells expressing the cloned receptor — proving this receptor could itself detect extracellular calcium as a ligand, unusual for a GPCR whose ligands are typically hormones or neurotransmitters, not an ion. This was the calcium-sensing receptor (CaSR). Subsequent human genetics sealed the causal link: loss-of-function CaSR mutations cause familial hypocalciuric hypercalcemia (the receptor under-senses calcium, so PTH is inappropriately not suppressed, and the kidney over-reabsorbs calcium), while gain-of-function mutations cause autosomal dominant hypocalcemia (the receptor over-senses calcium, suppressing PTH and lowering plasma calcium at a lower-than-normal set point). These human phenotypes, mirroring predictions from the cloned receptor's biochemistry, were powerful genetic confirmation that CaSR is the physiological calcium sensor.

Vitamin D deficiency, rickets, and the liver–kidney activation sequence. Rickets — bone deformity in children from inadequate mineralization — was long linked empirically to diet and sunlight (cod liver oil and sunlight exposure both cured it), but the mechanism was unclear until biochemists in the 1960s–70s (notably Hector DeLuca's group) used radiolabeled vitamin D₃ (³H-labeled) administered to animals and tracked its metabolic fate by chromatography of blood and tissue extracts. They found the label accumulated first as 25-hydroxyvitamin D in liver, then a second, more polar and more biologically potent metabolite appeared specifically after passage through kidney tissue. Nephrectomized animals failed to produce this second metabolite and failed to show enhanced intestinal calcium absorption when given vitamin D₃, whereas administering the already-activated 1,25-dihydroxyvitamin D₃ metabolite directly bypassed the need for kidneys entirely and restored calcium absorption. This nephrectomy-bypass experiment was decisive: it proved the kidney is an obligatory activation site, and it explains clinically why chronic kidney disease causes calcitriol deficiency and secondary hyperparathyroidism even when dietary vitamin D and liver function are normal.

Example 1 — Interpreting a lab panel: primary vs. secondary hyperparathyroidism. A 58-year-old woman has:

Reasoning: calcium is high, phosphate is low, and PTH is high. If this were appropriate physiological compensation (secondary hyperparathyroidism, e.g., from vitamin D deficiency or renal failure), we would expect PTH to be high because calcium is low — but here calcium is high, not low. A high PTH in the face of already-high calcium means the parathyroid is not responding to feedback — it is autonomously secreting PTH regardless of the calcium level, most consistent with a parathyroid adenoma (primary hyperparathyroidism). This fits the classic biochemical fingerprint Albright described: high calcium, low phosphate (from PTH-driven phosphaturia), and elevated PTH that fails to suppress. Contrast this with vitamin D deficiency, where low calcitriol causes low plasma calcium, appropriately high PTH (secondary hyperparathyroidism), but plasma phosphate is often low-to-normal for a different reason (reduced gut phosphate absorption plus PTH-driven renal phosphate wasting), and correction of the underlying vitamin D deficiency — not parathyroid surgery — resolves it.

Example 2 — Quantifying renal calcium handling. Suppose glomerular filtration rate (GFR) is 125 mL/min, plasma ionized calcium is 5 mg/dL (roughly half of a total calcium of 10 mg/dL, since ~50% is protein-bound/complexed and not filtered), and under high PTH conditions 99% of filtered calcium is reabsorbed (versus a baseline of ~98%). Filtered load of calcium = GFR × filterable plasma calcium concentration: Filtered load = 125 mL/min × 0.05 mg/mL = 6.25 mg/min At 98% reabsorption (baseline): excretion = 6.25 × 0.02 = 0.125 mg/min → over 24 hours ≈ 180 mg/day. At 99% reabsorption (high PTH): excretion = 6.25 × 0.01 = 0.0625 mg/min → over 24 hours ≈ 90 mg/day. This shows that a seemingly small shift in fractional reabsorption — 98% to 99%, just one percentage point — halves daily urinary calcium loss, illustrating why PTH's renal action, though quantitatively modest in percentage terms, is physiologically powerful in absolute terms. This also explains why hypoparathyroidism (low PTH) classically causes hypercalciuria despite low plasma calcium: without PTH's reabsorptive drive, the kidney "wastes" a higher fraction of the already-reduced filtered calcium, worsening the deficit — a maladaptive amplification that clinicians must correct for when dosing calcium and vitamin D supplements in these patients.

Clinically, this axis underlies the diagnosis and treatment of the most common calcium disorders: primary hyperparathyroidism (usually a parathyroid adenoma, treated surgically), secondary hyperparathyroidism of chronic kidney disease (failing kidneys cannot activate calcitriol or excrete phosphate, driving PTH up chronically and causing renal osteodystrophy — treated with active vitamin D analogs and phosphate binders), and osteoporosis, where drugs like denosumab work by directly blocking RANKL — mimicking, in effect, what OPG normally does to restrain osteoclast formation. Bisphosphonates, another major osteoporosis therapy, exploit osteoclast biology by binding hydroxyapatite and inducing osteoclast apoptosis once ingested during resorption. In endocrinology and surgery, teriparatide (recombinant PTH 1-34) is used, paradoxically, as an anabolic bone-building drug: intermittent, pulsatile PTH dosing favors osteoblast activity and net bone formation, whereas the chronically elevated PTH of hyperparathyroidism favors net resorption — a striking example of how the pattern of hormone exposure (pulsatile vs. sustained), not just its presence, determines physiological outcome. In nephrology, calcimimetic drugs (e.g., cinacalcet) allosterically activate CaSR, tricking parathyroid cells into "sensing" more calcium than is present, suppressing PTH in dialysis patients with intractable secondary hyperparathyroidism — a direct pharmacological exploitation of the Brown CaSR discovery. In public health and pediatrics, vitamin D fortification of foods (a direct application of the DeLuca activation pathway work) has nearly eliminated nutritional rickets in many countries, and vitamin D/calcium supplementation guidelines for older adults are grounded in this same bone-kidney-gut circuit. In veterinary and agricultural science, milk fever in dairy cattle (acute post-calving hypocalcemia from massive calcium loss into milk before PTH/calcitriol compensation catches up) is managed by anticipating and pre-treating this exact physiological lag. Together these applications show the calcium-phosphate axis as a rare case where a classical, decades-old physiological circuit maps almost one-to-one onto modern molecular drug targets.

Ask the tutor: How would this feedback loop respond differently in a patient with chronic kidney disease versus one with simple dietary vitamin D deficiency?